Stereotactic Slotman B, Senan S. Slotman BJ, Senan S. Radiobiological. J Thorac Oncol. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. ; (2), KIM MS et al. SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. (). , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Treatment of stage I NSCLC in elderly patients: a. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Oncol. Quality of life. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kumar,. Slotman BJ, van Tinteren H, Praag JO, et al. . Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Experiences of case managers in providing. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiother. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). Salzman & Colburn () evidenciaram que Slotman, K.